Form 4: MannKind Executive Stuart A. Tross Reports Stock Transactions Following RSU Vesting

Stuart A. Tross, Chief People & Workplace Officer at MannKind Corp, reports acquisition and disposal of shares related to vesting of restricted stock units (RSUs) and tax obligations.

Summary

• On May 10, 2025, Stuart A. Tross acquired 105,600 shares of MannKind common stock due to the vesting of a previously reported restricted stock unit award.
• The vesting was contingent upon achieving performance objectives related to MannKind's stock price and total shareholder return (TSR).
• The performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares.
• On May 12, 2025, Tross disposed of 88,724 shares at $4.56 to cover exercise price or tax liability related to the vesting of the RSUs.
• An additional 8,051 shares were disposed of on the same day at $4.56 for the same reason.
• On May 13, 2025, Tross acquired 119,000 shares pursuant to a new Restricted Stock Unit Award that vests in 25% increments annually starting July 15, 2026.
• Tross also acquired 145,000 performance-based restricted stock units that will vest on July 15, 2028, based on MannKind's TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and the achievement of performance objectives, suggesting a moderately positive outlook. The disposal of shares for tax purposes is neutral.

Positives

• The vesting of the restricted stock unit award indicates that MannKind met certain performance objectives related to stock price and total shareholder return.
• The performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares.
• The grant of new restricted stock units incentivizes the executive to continue driving company performance.

Negatives

• The disposal of shares to cover tax liabilities reduces the executive's direct ownership stake in the company, although this is a common practice.

Risks

• Future vesting of performance-based restricted stock units is contingent on MannKind's TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index, which is subject to market volatility and competitive pressures.
• Failure to meet the TSR targets could result in a lower payout or no payout of the performance-based restricted stock units.

Future Outlook

The future vesting of restricted stock units is dependent on continued employment and, in the case of performance-based units, on MannKind's TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index.

Industry Context

Executive compensation through stock options and restricted stock units is a common practice in the pharmaceutical and biotechnology industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Comparing MannKind's executive compensation structure to companies like Amgen, Biogen, or Gilead Sciences would provide a benchmark for assessing the competitiveness and appropriateness of the compensation package.
• The use of TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index is a common metric for performance-based compensation in the industry, ensuring that executives are incentivized to outperform their peers.

Stakeholder Impact

• Shareholders may view the vesting of restricted stock units as a positive sign, indicating that the company is meeting its performance goals.
• Employees may be motivated by the opportunity to participate in equity ownership through stock purchase plans and restricted stock unit awards.

Next Steps

• Continued monitoring of MannKind's stock price and TSR performance to assess the potential vesting of future restricted stock units.

Key Dates

Keywords

MannKind, MNKD, Stuart A. Tross, Restricted Stock Units, RSU, Vesting, Form 4, Total Shareholder Return, TSR, Executive Compensation